<DOC>
	<DOCNO>NCT00002285</DOCNO>
	<brief_summary>To determine safety efficacy zidovudine ( AZT ) treatment combine syngeneic HLA identical allogeneic lymphocyte transfer presence interleukin 2 ( IL-2 ) treatment AIDS . Patients document HIV viremia evaluate . Effects virus replication , immune function , clinical condition monitor periodic virus culture , estimate lymphocyte type number , cell surface marker , vitro lymphocyte response frequent clinical evaluation .</brief_summary>
	<brief_title>A Study Zidovudine T Lymphocyte Transfer Treatment HIV Type III Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Coexisting Condition : Patients follow exclude : Lymphoma . Active central nervous system ( CNS ) infection bacteria , varicella zoster virus , herpes simplex virus , Cryptococcus neoformans . Any prior CNS infection due Toxoplasma gondii . Any active lifethreatening infection include Pneumocystis carinii pneumonia ( PCP ) ( prior PCP prePCP arterial PO2 must 80 ) , disseminate cryptococcosis ( prior cryptococcosis infection patient must negative blood cerebrospinal fluid ( CSF ) culture take 6 week last antifungal therapy ) . Any prior mycobacterium aviumintracellulare isolation . Patients follow condition exclude : Lymphoma . Active central nervous system ( CNS ) infection bacteria , varicella zoster virus , herpes simplex virus , Cryptococcus neoformans . Any prior CNS infection due Toxoplasma gondii . Any active lifethreatening infection include Pneumocystis carinii pneumonia ( PCP ) ( prior PCP prePCP arterial PO2 must 80 ) , disseminate cryptococcosis ( prior cryptococcosis infection patient must negative blood cerebrospinal fluid ( CSF ) culture take 6 week last antifungal therapy ) . Any prior mycobacterium aviumintracellulare isolation . Patients accept allogenic cell transfer must meet CDC criterion AIDS . Those patient meet criterion Kaposi 's sarcoma must also history generalize lymphadenopathy ( CDC category III ) , neurologic disease ( CDC category IVB ) , constitutional disease ( CDC category IVA ) . Patients may accept syngeneic cell transfer even meet CDC AIDS criterion , provide constitutional disease ( CDC category IVA ) specify nonAIDS define secondary infection ( CDC category IVC2 ) . Patients must positive blood culture AIDS virus begin therapy . Patients must skin test negative PPD . Patients must life expectancy least 6 month Karnofsky status 60 . Patients must sign informed consent agreement . From eligible patient precedence give identical twin donor , Minnesota resident . The first patient must identical twin donor . Among eligible Minnesota patient without identical twin donor , order enrollment determine overall good health , presence Kaposi 's sarcoma ( permit monitor response measure lesion ) and/or presence cytomegalovirus ( CMV ) viremia ( permit monitor response remission CMV viremia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1995</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>Pilot Projects</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Transplantation , Homologous</keyword>
	<keyword>Zidovudine</keyword>
</DOC>